Literature DB >> 31853148

For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?

.   

Abstract

Entities:  

Year:  2019        PMID： 31853148      PMCID： PMC6910845     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  21 in total

Review 1.  New antiplatelet agents for cardiovascular disease.

Authors:  Doson Chua; Cesilia Nishi
Journal:  CMAJ       Date:  2013-09-09       Impact factor: 8.262

2.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2019-01-28       Impact factor: 24.094

3.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine
Journal:  Eur Heart J       Date:  2018-01-14       Impact factor: 29.983

4.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.

Authors:  Morten L Hansen; Rikke Sørensen; Mette T Clausen; Marie Louise Fog-Petersen; Jakob Raunsø; Niels Gadsbøll; Gunnar H Gislason; Fredrik Folke; Søren S Andersen; Tina K Schramm; Steen Z Abildstrøm; Henrik E Poulsen; Lars Køber; Christian Torp-Pedersen
Journal:  Arch Intern Med       Date:  2010-09-13

5.  Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.

Authors:  Renato D Lopes; Hwanhee Hong; Ralf E Harskamp; Deepak L Bhatt; Roxana Mehran; Christopher P Cannon; Christopher B Granger; Freek W A Verheugt; Jianghao Li; Jurriën M Ten Berg; Nikolaus Sarafoff; C Michael Gibson; John H Alexander
Journal:  JAMA Cardiol       Date:  2019-08-01       Impact factor: 14.676

6.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

Review 7.  Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications.

Authors:  Joern Schmitt; Gabor Duray; Bernard J Gersh; Stefan H Hohnloser
Journal:  Eur Heart J       Date:  2008-12-24       Impact factor: 29.983

8.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Authors:  C Michael Gibson; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W Verheugt; Peter Wildgoose; Mary Birmingham; Juliana Ianus; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Gregory Y H Lip; Marc Cohen; Steen Husted; Eric D Peterson; Keith A Fox
Journal:  N Engl J Med       Date:  2016-11-14       Impact factor: 91.245

9.  An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.

Authors:  Renato D Lopes; Amit N Vora; Danny Liaw; Christopher B Granger; Harald Darius; Shaun G Goodman; Roxana Mehran; Stephan Windecker; John H Alexander
Journal:  Am Heart J       Date:  2018-03-09       Impact factor: 4.749

10.  Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography.

Authors:  Stefan Kralev; Kathrin Schneider; Siegfried Lang; Tim Süselbeck; Martin Borggrefe
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.